The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Final analysis of Panorama 1: Phase 3 trial of panobinostat for multiple myeloma
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, discusses the final analysis of overall survival from Panorama 1, a phase 3 clinical trial that evaluated panobinostat, a histone deacetylase inhibitor, plus bortezomib, a proteasome inhibitor, and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
